ῌ,**/ The Japanese Society for AIDS Research /  ECC The Journal of AIDS Research   HIV!"#$%&' HIV () Research for Novel Anti-HIV Agents Which Inhibit R/ HIV-+through Their Antagonistic E#ects on CCR/   Kenji MAEDA


 

Department of Hematology, Kumamoto University Graduate School of Medicine
 National Cancer Institute, National Institutes of Health, USA 1 : ++*῍++0 ,**/

=@A> ^{()l#V!&9<=h*+,->6()* dq#71%FB>C()9 HIV @1&. + <=DEFῌGHI>1\/  ECC 

 !"#$%&'()*.

+ ,-()@ GH1\@ , <= DNA J DNA  #&/0

K>1\()@ Q_RO`1\@ -

1"234)*&.

<=ObQRῌ%I#F()@IEUqe&+K L#GH1\@#$%&.#%m/0")123$j@EMNῌMNO383+K

AIDS 5678 #()9 HIV :;

Pq2 HIV GH1\@ + $34)Qa]

6<= >%"? @

NO1\@>38p&M"* HIV . Q)D

HAART .AB>CD&%)E F ῌ

#EFῌGH() CD. R,#Qa]!

" @#$GH%

IJ&E'1&+NO e)R>¡a]NO1&%)E CCR

B>CD"?. +33* *+5,#.

/ .WQa]NO + $34K R/-HIV ¢M NOPQRSQ;>TU&%"%!&V%* W{^£¤Ob¥¦ HIV %§e) HIV ¨S#TU

VX -334)de)* ©3. CCR/ >Q)1& HIV >2

K (L).9 HIV @ Y/Z[01\@ῌ]^_O`1\@ 3@#$GH% >23()abQc4Ede)f# @#$GH#2g
5 h>i1 j$@#6 klK#m%7n@o6E8pqe&%)+, ,*r AIDS s , 

9 + $34)Y/Z[01\@RTIs #. RT

Y/

3() CCR/ 1\@#$%&Vª)* 45(6*HIV DGH.« HIV WXY34) gp+,*

EDZ[ CD. y()l3¬)* y#VK

Z[0 :tu vw xy)#F()z{agp+,* ­\$?EklK Q~a]NO|}~Y/Z[01\@ NRTIs  h-;<#]NO 34)Qa]NOy WB

y1&tu>=xy)#1\()=z{a|}~Y/<=]XY gp.+ EWZ[#^E_`de& gp.+

Z[01\@ NNRTIs Ee)* A> ]^_O`

abEQ)Dcd#eHde gp.+ -#.r() ,1\@PIs . HIV ]^_O`?M>1\1 <Pqra : Kenji Maeda, M.D., Ph. D.
Experimental Retrovirology Section, HIV & AIDS
Malignancy Branch
National Cancer Institute, National Institutes of
HealthBuilding +*//A++, 3*** Rockville Pike, Bethesda,
MD ,*23,, USA
Fax : »+῍-*+῍.*,῍*1*3,**/ * / ¼ ,.  s

++*

/* 

$®O]¯¡a

HR+ῌHR, Ey1&®°QO]>±1<=².JDc#fy <=ghED#iKe&³j()de&%)* Qa]NO. GPCR G XYfk´gl £¤µO#m()* GPCR #. b ~a¶Q gl Inl#op k·>1&%)2Eme&+K ¸¹F>C()@NOº;1&op34)* le3#¸¹Qa]NO CXCR,ῌ

The Journal of AIDS Research Vol. 1

CCR,ῌCCR-ῌCCR/  

   !"#$%&' () *'&+,-."*#/0"123456
78&'! "9 HIV /  
JKLM+N>

=>9 CCR/ : R/

BQR S

,**/

78&' >9

CCR/  : spirodiketopiperazine SDP : +330 ; / CCR / <CXCR. #!=>?@ABCDEFGH HIV 4IDE

FGH#

No. ,

56^: CCR / #j4p

C^t" CC-!"*#O&P#

chemokine SMIP-+ #4+,-."4RT H

TUVWHXYZC+ ?@ABC4 binding assay (0 Ca, ﬂux in-

BQR

hibition assay ^=>9 j4N CCR/ +.":_`abP& AIDS cdef^gh i&'"9 j'HIV /[\]'" HIV 4IDEFGH^

4 : spirodiketopiperazine SSDP  |+¡¢/k

FUGBF4^t" E3+*

CXCR. : X.

R/

BQR#!lmb4nopeb/qr." HIV s!"IDEFGH^t"9
CCR/ /u! :vw4x +῍/i&'" CCR/ +yz>{| SCCR/ }-,  HIV 4_`/~^t"#]'Pj40l CCR/ yz4{|i-^t"#!lP& CCR/ : dispensable ^t)GH
#

+

,

p^t"#

CCR/ ,-4c

E3+- S£ +. 4!¤' MIP-+a 4 CCR/-CHO ¥¦4+,->
MCP-+ 4 CCR, cr¥¦4/:§¨+%P=

> S£ ,9 ©¥¦ªAQ«¬,-/u!

E3+-: MIP-+a SCCR/ 4­*.:,-> MDC
SCCR.

0=

SDF-+a SCXCR. ]&/ MCP-+ SCCR, /®­*]'"AQ«¬/:§¨+%

Spirodiketopiperazine SSDP  | SCCR/ ,-
E3+- # AK0*, :!¤' spirodiketopiperazine ¯°+±²³/´u CCR/ ,-^t"9SDP |: CCR/ # MIP-+a 4+,-."+,/

I-µ¶Q>?@ABC#?@ABCDEFGH4,-·¸^ SDP  |:?@ABCSMIP-+a# CCR/ 4+,-> S¹£ CCR, #?@ABC SMCP-+ 4:,-P=> Sº£9+++S /+ 

K Maeda : Research for Novel Anti-HIV Agents Which Inhibit R/ HIV-+ through Their Antagonistic E#ects on CCR/

SDPῌ  chemotaxis  -   !"#$%&'PBM 2ῌA p,. FGH2ῌ E3+- 8 R/ #H!

*IA HIV-+BaL JKL HIV-+JRFL 59

M-N HIV()*+,-./01ῌ2345

OP234 Q + RSN HIV T UVWXYZ[ data not shown

T : RTIs \]^_`Z[T : PIsa?2bc#H!

= +,1) deῌfTa?ΐgh

SDP ῔ῒῑῌ῎ HIV ῍ῐ

῏=8ij*kl 3m++ n῔ N HIV T2opkTq

 HIV-+BaL R/ HIV-+ and HIV-ῌῑC2rstuv c* I wAxῑ M-OP2+NL.-- X. HIV-+ 59 HIV-+ :;<=*>?+,b5y5 AIDS z{K|h῏0 /01 RT ῒ2) >?2@4ABC-8 PHA *DE-} PR ῒ} kla?~2-J| in vitro *1

678 E3+-

nN HIV T a?2b-/ de+,*1
0fTa?=8/01 AZT, NFV nelfinavir

SQV saquinavir

M-a?234. E3+- 8 R/ 

a?#H!*IA HIV-+JSL  HIV-+MM fT

u?2bcΐgh῏=*IA R/ HIV-+MOKW  
>?2- Q +  678 optimization 24 N HIV >?f2y
AK0*,ῌONO.+,2ῌGW21-+.*  +0 2 - AK0*,

8 E3+- K| R/ #H! M- +**ῌ2** N HIV >? 0J| E3+-   kTa?ΐgh῏ R/-HIV=

M-1fTu?=

N HIV >?2- Q + B* E3+- JKL AK0*, 8 HIV-+NL.- X. HIV-+

8OP234/ 085A2cA

CCR/ Z[T TAK-113 JKL SCH-C1, 2 *1
῏ -,¬E3+- 8 CCR/ 2«- ¡ H¢ Ca ()2Z[cA¡ H¢­G\®_ ¡ H¢.¯°c
A%&'± Ca,¬ () ²³F´ῐµ.¶A. E3+- 8 CCR/

KA Ca,¬ ()·2῎-*I 0

M- CXCR. Z[T*IA AMD--+** 8 X. HIV *IA HIV-+NL.- 2῎-. R/ n HIV-+ =῎OP85 Q +  ¡ H¢
 HIV £῕  CC-chemokine . X. #H!¤¥2¦ IA8 SDF-+ . R/ #H!¤¥2§rc
A¨©.IA.3 E3+- JKLª SDP

8+

ΐ + CCR/ Z[TN HIV >?
IC/* valuea in p,. assay (nM)aabcompound

HIV-+Ba-L(R/)

HIV-+JR-FL(R/)

HIV-+MOKWb(R/)

HIV-+MMb(R/MDR)

HIV-+JSLb(R/MDR)

HIV-+NL.ῌ(X.)

AK0*,
E3+TAK-113
SCH-C
AZT
NFV
SQV
AMD--+**

*..
2,
,2
.
1
+,
++
¸+***

*.+
2+
/
,
+*
n.d.
n.d.
¸+***

*.,
/+
++
,
0
+.
/
¸+***

*.0
0+
+.
,/*
¸+***
-**
¸+***

*..
0.
1
,
1*
¸+***
-/*
¸+***

¸+***
¸+***
¸+***
¸+***
++
,*
+*
0

IC/* value : #H!¤¥2 /*ῌ ῎cAfT¹º
HIV-+MOKW 8»xῑ HIV ῍?z{ h῏0 HIV = HIV-+MM  HIV-+JSL 8ΐg¼
h῏0=++,  /, 

fTa?2bcz{The Journal of AIDS Research Vol. 1

mM 



data not shown E3+-  PHA-PBM 

$_ CCR/

No. ,

,**/

i( - CCR/ ./!" CCR/ "$ 01)$ l$0

AK0*, !"#$ $%& selectivity index

 CCR/ $*A:>9$+

SI  +,3/ ' AK0*, ( SI  ,*¥;¦§"¨,©Txy$H)01#ªB )"*+,- %&# data not shown

CCR/ 

0 «$ CCR/ ./!' TAK-113 X
SCH-C1, 2 $01-¬"­®_2"O" .¯°/R 2NO$0 $_ CCR/ .

CCR/ ./! CCR/ 012" HIV $34./5 CCR/ $6$H)¡¢£¤

789:' CCῌ

;<=>9$? ./ @$AB 6 CCR/ /!$01-¬lN±N_ªB 0 $²1$
}S>TU


1³´µ¶x·""¸+N

2$aq v( 2" CCR/

CD#EF CCR/ G-, HIJK' LM2NO$PQ$RS>TU34VWXYZ[\5$]^W_`"-abO
N+*, ++  CCR/ cdEF$ CCR/ $*ef.
/2" gO$h$? iNjk*- l2 CCR/ 01;<=>9mncd$o pqrs " HIV ./? $t
_;<=>9?u#v#"2w;<=>9$
NH, Txy$z{Lp2" ;<=>9$01

|*(2"} HIV ?
2"O"B+, 2$0$~N

O} HIV $~p# CCR/ ./! $jON 
O AK0*, $} HIV ";<=>9././?
$t"#v#"2w AK0*, !`"

CCR/ 01# KD  : - nM cO . ;<=>9 RANTES $ CCR/ $01+#$-2"%B  / CCR/ #6 ? &2"6?  AK0*, -j&N
2$aq  Q'

 /

 .

AK0*,  CCR/ "01#
cd-

H ¹ºT# AK0*, " CCR/  i» - AK0*, $01#¼"2
w AK 0*,   "  CCR /  $ 0 1  # 
KD  : ,.3 nM #-SDP 23F RANTES " CCR/ $01ef./#AK0*, s$ SDP 23F MIP-+a " CCR/ $01ef./ C
B " CCR/ $01ef./#-

RANTES A++-

MIP-+b /- 

K Maeda : Research for Novel Anti-HIV Agents Which Inhibit R/ HIV-+ through Their Antagonistic E#ects on CCR/  HIV   HIV  CCR/ !

 X.ῌR/ῌdual tropic :;%<;2
 HIV 5 ? @  2 A  CCR /  

CXCR. "#$%&'()* HIV 

9
=>

B

"CDEF5G)6H

I5J%KLG)* MN" E3+- % CXCR. "J AMD--+** %O R/ / 01% X. /

 + + E3+- , AK0*,  CXCR. -.%/ 01 234565 AIDS 78

01?@P J6 CXCR. CCR/ 8Q
RSTUV%26N%"# dual tropic /01 2WX34$GYZ%N[N)G \]F34+ ^ 1 * B_`a HIV  bcde  TfghVi
%"$=jklIm"\]n\o34+
p"$q %"34rstus5+() data not shown ., +- *in vivo  HIV 
v w  AK0*,  in vivo "a HIV rsx; y/1z0 NOD-SCID AIDS y/1z0 "a HIV x{| Nz0"}~6/01%ῌ CD.

s!6

5$G()5   + "# AK0*, +,*
+.

mgῌkg

$%N%"/ 01 &'

 , log
 0 AK0*, % CCR/ ¤I
AK0*,  CCR/ * , !¥¦§ % CD.ῌCD2 (}$GN%

5Y ^ 2 +/ *ECL

, : ¨ ©ª."J G+0- % K+3+ ,«./¬¦§
TM domain ­. Y+*2
W 0®" CCR/ ¯¤I1°XN%
YG AK0*,  ECL, %«./¬¦§Y
G±()²³¤I%´m)*AK0*, GW21-+.* @ ) 

11
ῌHIV

 p5m)26* s78 p* , \ Phase IIaq _'8$

HIV

"

s78  +* "¡$%"+ +.0 log + " , ¢ £ 0** mg $% /01, -;26+0 * 1 CCR/  % CXCR.  34
R/-HIV HIV-+BaL % X.-HIV HIV-+NL.ῌ- ?I( E3+- % AMD-+** 34Z*M¤4 N?I/ 01 + "µ¶F"#Y$ , "µ¶F() ·^  Prichard G¸¹2+2 "6\] º»N%53GY ¼^ *++.  /.

The Journal of AIDS Research Vol. 1

ΐ 2

SCID ²OQ# ³PNO#PQR
NOD-SCID ²OQR L PBM ,´µ S³P R/ HIV ,J

No. ,

,**/

S J5V|f ddI AK

0*, W¶XYZ,·0 AK0*, YZ¸ CD.ῌCD2 [\¹L º]d ^¸[H_ , log
O#PQ`»U,a ¼]d

#&d 8$XS HIV Jtg,$Xῌ῏῎῍HIV F& CCR/ $XV!D HAART    HAART +33* Hit early, hit hard    !"#$%#& CD.

,** ῌ mm- () *+,-.







 RTIs NRTIsῌNNRTIsd  PIs :  , 7
G=2 CCR/ $XVTH3?IJ
 HIV JK

'



0

T03A DTL

K2

JK 

/0   123456 7
8 9:;<=2 HAART , )

ῒῑ :  ECC P#

>3?4@ABC DE,£¢ St E> :¤¥)? 7¢:-.F GH: HAART ¦§¨©NDO Pª«/( 0¬7Q­R

I AIDS  HIV JK3L?

S®¯,°±NDOTU?iz)



>MNO#PQR , ?  ,! ST8
UTV! "#E:</>

῔

YZ¡M¢

ῐ

T W:T  CCR/ $XV!YZ%[&+ d Mitsuya H, Erickson J : Discovery and development of'(,\)YZ]P^_ῌ*`ab?

antiretroviral therapeutics for HIV infection, (Merigan!YZc+ E  ,ef YZ,-g SDP

TC, Bartlet JG, Bolognesi D eds.), Textbook of AIDS./0 + hE AK0*, 4iG1> j2k3 ,Medicine, Williams & Wilkins, Baltimore, p1/+ῌp12*,+1d4lmnT56,o
7YZpq? r8,2klm9s):tgT3 CCR/ ,u? HIV Jvw;

+333.
, d Fauci AS : HIV and AIDS : ,* years of science. Nat
Med 3 : 2-3ῌ2.-, ,**-.

<&T=x,>f  yzf   f- d Liu R, Paxton WA, Choe S, Ceradini D, Martin SR,

5{|f7}~T CCR/ $XV?

Horuk R, MacDonald ME, Stuhlmann H, Koup RA,

W  T0>@4 {,A

Landau NR : Homozygous defect in HIV-+ coreceptor

D E CCR/ "&$CB&C, : CCR/ ,u?DE&T 

accounts for resistance of some multiply-exposed individuals to HIV-+ infection. Cell 20 : -01ῌ-11, +330.

++/

 // dK Maeda : Research for Novel Anti-HIV Agents Which Inhibit R/ HIV-+ through Their Antagonistic E#ects on CCR/

. ῍ Maeda K, Yoshimura K, Shibayama K, Habashita H,+,, : +1,+ῌ+1,2, ,**,.

Tada H, Sagawa K, Miyakawa T, Aoki M, Fukushima++῍ Fischereder M, Luckow B, Hocher B, Wuthrich RP,

D, Mitsuya H : Novel low molecular weight spirodi-

Rothenpieler U, Schneeberger H, Panzer U, Stahl RA,

ketopiperazine derivatives potently inhibit R/ HIV-+ in-

Hauser IA, Budde K, Neumayer H, Kramer BK, Landfection through their antagonistic e#ects on CCR/. J Biol

W, Schlondor# D : CC chemokine receptor / and renal-

Chem ,10 : -/+3.ῌ-/,**, ,**+.

transplant survival. Lancet -/1 : +1/2ῌ+10+, ,**+.

/ ῍ Yoshimura K, Kato R, Yusa K, Kavlick MF, Maroun V,+,῍ Miyakawa T, Obaru K, Maeda K, Harada S, Mitsuya

Nguyen A, Mimoto T, Ueno T, Shintani M, Falloon J,

H : Identiﬁcation of amino acid residues critical for LD

Masur H, Hayashi H, Erickson J, Mitsuya H : JE-,+.1 :12b (a variant of human macrophage inﬂammatory pro-a dipeptide protease inhibitor (PI) that potently inhibits

tein-+a) binding to CCR/ and inhibition of R/ HIV-+

multi-PI-resistant HIV-+. Proc Natl Acad Sci USA 30 :replication. J Biol Chem ,11 : .0.3ῌ.0//, ,**,.

201/ῌ202*, +333.
0 ῍ Maeda K, Nakata H, Koh Y, Miyakawa T, Ogata H,+-῍ Nakata H, Koh Y, Maeda K, Takaoka Y, Tamamura H,
Fujii N, Mitsuya H : Presented at The +,th Conference

Takaoka Y, Shibayama S, Sagawa K, Fukushima D,

on Retroviruses and Opportunistic Infections, Boston,Moravek J, Koyanagi Y, Mitsuya H : Spirodiketo-

MA, February ,,ῌ,/, ,**/.

piperazine-based CCR/ inhibitor which preserves CC-+.῍ Miura Y, Misawa N, Maeda N, Inagaki Y, Tanaka Y, Ito

chemokine/CCR/ interactions and exerts potent activity

M, Kayagaki N, Yamamoto N, Yagita H, Mizusawa H,

against R/ human immunodeﬁciency virus type + in

Koyanagi Y : Critical contribution of tumor necrosis

vitro. J Virol 12 : 20/.ῌ200,, ,**..

factor-related apoptosis-inducing ligand (TRAIL) to

1 ῍ Baba M, Nishimura O, Kanzaki N, Okamoto M, Sawada

apoptosis of human CD.῎ T cells in HIV-+-infected

H, Iizawa Y, Shiraishi M, Aramaki Y, Okonogi K,

hu-PBL-NOD-SCID mice. J Exp Med +3- : 0/+ῌ00*,

Ogawa Y, Meguro K, Fujino MA : Small-molecule, non-,**+.

peptide CCR/ antagonist with highly potent and selective+/῍ Nakata H, Maeda K, Miyakawa T, Shibayama S, Matsuo

anti-HIV-+ activity. Proc Natl Acad Sci USA 30 : /032ῌ

M, Takaoka Y, Ito M, Koyanagi Y, Mitsuya H : Potent/1*-, +333.

anti-R/ human immunodeﬁciency virus type + e#ects of

2 ῍ Strizki JM, Xu S, Wagner NE, Wojcik L, Liu J, Hou Y,

a CCR/ antagonist, AK0*,/ONO.+,2/GW21-+.*, inEndres M, Palani A, Shapiro S, Clader JW, Greenlee WJ,

a novel human peripheral blood mononuclear cell non-Tagat JR, McCombie S, Cox K, Fawzi AB, Chou CC,obese diabetic-SCID, interleukin-, receptor g-chain-

Pugliese-Sivo C, Davies L, Moreno ME, Ho DD, Trkola

knocked-out AIDS mouse model. J Virol 13 : ,*21ῌ,*30,

A, Stoddart CA, Moore JP, Reyes GR, Baroudy BM :,**/.

SCH-C (SCH -/++,/), an orally bioavailable, small mol-+0῍ Lalezari J, Thompson M, Kumar P, Piliero P, Davey R,

ecule antagonist of the chemokine receptor CCR/, is a

Murtaugh T, Patterson K, Shachoy-Clark A, Adkison K,

potent inhibitor of HIV-+ infection in vitro and in vivo.

Demarest J, Sparks S, Fang L, Lou M, Berrey M,

Proc Natl Acad Sci USA 32 : +,1+2ῌ+,1,-, ,**+.

Piscitelli S : Presented at the ./th Interscience Confer-

3 ῍ Moriuchi H, Moriuchi M, Fauci AS : Factors secreted

ence on Antimicrobial Agents and Chemotherapy, Wash-by human T lymphotropic virus type I (HTLV-I)-

ington, DC, October -*ῌ November ,, ,**..

infected cells can enhance or inhibit replication of HIV-

+1῍ Maeda K, Nakata H, Ogata H, Koh Y, Miyakawa T,+ in HTLV-I-uninfected cells : implications for in vivo

Mitsuya H : The current status of, and challenges in, thecoinfection with HTLV-I and HIV-+. J Exp Med +21 :development of CCR/ inhibitors as therapeutics for+023ῌ+031, +332.

HIV-+ infection. Curr Opin Pharmacol . : ..1ῌ./,,+*῍ Woitas RP, Ahlenstiel G, Iwan A, Rockstroh JK,,**..

Brackmann HH, Kupfer B, Matz B, O#ergeld R,+2῍ Prichard MN, Prichard LE, Shipman C Jr : Strategic

Sauerbruch T, Spengler U : Frequency of the HIV-

design and three-dimensional analysis of antiviral drug

protective CC chemokine receptor /-Delta-,/Delta-,

combinations. Antimicrob Agents Chemother -1 : /.*ῌ

genotype is increased in hepatitis C. Gastroenterology/./, +33-.

++0 ῌ /0 ῍